Impact ledger
Skye Bioscience, Inc. (SKYE): the developments shaping its investment case
Follow the evidence affecting Skye Bioscience, Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-15 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-08-15 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-08-15 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
Event impact log
2 events mapped to SKYE since 2026-08-14. Evidence through 2026-08-18.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-08-18 | Skye Bioscience, Inc. Announces Proposed Acquisition of Redx Pharma Limited | Direct impact of delisting notice and uncertainty surrounding acquisition financing/completion. | Bearish | 1-5d | 0.90 |
| 2026-08-14 | Skye Bioscience, Inc. to Acquire Redx Pharma Limited ($125M) | Direct acquisition of a complementary asset, financed by new capital, leading to potential dilution and integration risks but also pipeline expansion. | mixed | 3-12m | 0.60 |
Continue this research
Build your Skye Bioscience, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the SKYE entity page →